Celltrion Presents Positive Phase 3 Data for Actemra and Prolia Biosimilars at ACR 2024
核心洞察
Celltrion's CT-P47, a biosimilar of Actemra, demonstrated comparable efficacy, pharmacokinetics, safety, and immunogenicity in rheumatoid arthritis (搜索) patients over 52 weeks, including those switched from the original drug.
CT-P41, a biosimilar of Prolia, met the primary endpoint in a Phase 3 trial involving postmenopausal women with osteoporosis (搜索), showing similar efficacy and safety profiles to the original drug over 78 weeks.
Both CT-P47 and CT-P41 are currently under regulatory review in key global markets, including the United States and Europe, as part of Celltrion's next-generation biosimilar pipeline.
Celltrion presented global Phase 3 clinical data for its Actemra biosimilar, CT-P47, and Prolia biosimilar, CT-P41, at the 2024 American College of Rheumatology (ACR) Annual Meeting in Washington, D.C. The data, disclosed on November 19, reinforce the potential of these biosimilars to offer cost-effective alternatives for patients with rheumatoid arthritis (搜索) and osteoporosis (搜索).
CT-P47: Biosimilar for Rheumatoid Arthritis
The 52-week results of the global Phase 3 clinical trial of CT-P47, which enrolled 471 patients with rheumatoid arthritis (搜索) (RA), demonstrated sustained efficacy in patients who switched to CT-P47 from the original drug. The trial initially divided patients into two groups: one receiving CT-P47 and the other receiving the original drug for 24 weeks. At week 24, the group receiving the original drug was randomized to either continue with the original drug or switch to CT-P47. By week 52, secondary endpoints revealed no significant differences in efficacy, pharmacokinetics, safety, and immunogenicity across all three groups: those switched from the original drug to CT-P47, those who continued with the original drug, and those who continued with CT-P47 from the start. These findings suggest that switching to CT-P47 is a viable option for patients already on Actemra.
CT-P41: Biosimilar for Osteoporosis
Celltrion also presented Phase 3 results and post-hoc analysis data for CT-P41. The 78-week evaluation, conducted on 479 postmenopausal women with osteoporosis (搜索), demonstrated that CT-P41 met the primary efficacy endpoint, showing equivalence to the original drug. The study also confirmed similar efficacy and safety profiles up to week 78 in groups that switched to CT-P41 at week 52 and those that continued with either CT-P41 or the original drug. This indicates that CT-P41 could serve as an effective biosimilar alternative for postmenopausal women requiring treatment for osteoporosis.
Regulatory Status and Future Plans
Both CT-P47 and CT-P41 are currently undergoing approval procedures in major countries, including the U.S. and Europe. A Celltrion representative stated, "By additionally disclosing the global Phase 3 clinical data of CT-P47 and CT-P41 at this conference, we have once again confirmed their efficacy and safety. As these two biosimilars are part of Celltrion's next-generation pipeline, we will do our best to bring them to market as soon as possible."